Table 5 NNT for at least 50% pain relief in postsurgical pain
From: Individual patient meta-analysis of single-dose rofecoxib in postoperative pain
| Â | Â | Improved with | Â | Â | Mean percent improved with | ||
|---|---|---|---|---|---|---|---|
Time (hours) | Drug and dose (mg) | Active | Placebo | Relative risk (95% CI) | NNT (95% CI) | Placebo | Active |
6 | Rofecoxib 50 mg | 43/110 | 7/53 | 3.0 (1.4 to 6.1) | 3.9 (2.6 to 7.8) | 13 | 39 |
| Â | Naproxen 550 mg | 20/55 | 7/53 | 2.8 (1.3 to 6.0) | 4.3 (2.6 to 13) | 13 | 36 |
8 | Rofecoxib 50 mg | 44/110 | 6/53 | 3.5 (1.6 to 7.8) | 3.5 (2.4 to 6.9) | 11 | 40 |
| Â | Naproxen 550 mg | 18/55 | 6/53 | 2.9 (1.2 to 6.7) | 4.7 (2.7 to 16) | 11 | 33 |
12 | Rofecoxib 50 mg | 38/110 | 2/53 | 9.2 (2.3 to 37) | 3.3 (2.4 to 4.9) | 4 | 35 |
| Â | Naproxen 550 mg | 14/55 | 2/53 | 6.8 (1.6 to 28) | 4.6 (2.9 to 11) | 4 | 25 |